FORMULATION DEVELOPMENT AND CHARACTERIZATION OF LYOPHILIZED FEBUXOSTAT NANOSUSPENSION

Authors

  • ANKITA HADKE Datta Meghe College of Pharmacy, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha, Maharashtra, India 442001 https://orcid.org/0000-0001-7163-0307
  • ANIL PETHE Datta Meghe College of Pharmacy, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha, Maharashtra, India 442001 https://orcid.org/0000-0002-6380-1847
  • SUNITA VAIDYA Datta Meghe College of Pharmacy, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha, Maharashtra, India 442001 https://orcid.org/0000-0003-4395-6048
  • SUNIL DEWANI Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha, Maharashtra, India 442001 https://orcid.org/0000-0002-5457-4937

DOI:

https://doi.org/10.22159/ijap.2022v14i6.45614

Keywords:

Febuxostat, Nanosuspension, PVP K-30, Sodium lauryl sulfate, Lyophilization

Abstract

Objective: The study aims to prepare and evaluate febuxostat nanosuspension to improve oral bioavailability.

Methods: Febuxostat nanosuspension was prepared by the solvent-antisolvent method followed by a lyophilization technique using PVP K-30 as a stabilizer and sodium lauryl sulfate as a surfactant. Drug content, differential scanning calorimetry, powder x-ray diffraction, Fourier transform infrared spectroscopy, and in-vitro dissolution studies were used to characterize the nanosuspension.

Results: The results of the characterization studies indicated the formation of nanosuspension. The lyophilized FXT NS particle size is 2170.2 nm, the PDI value is 0.63, the negative zeta potential is 1.6 mV, and the drug content is 19.02%. Functional characterization studies demonstrated that the particle size reduced due to the interaction between the stabilizer and surfactant.

Conclusion: It can be concluded that the prepared febuxostat nanosuspension enhances the aqueous solubility of FXT and improves its oral bioavailability.

Downloads

Download data is not yet available.

References

Pawar PG, Darekar AB, Saudagar RB. Formulation development and evaluation of febuxostat loaded microsponges, Int. j. res. advent technol. 2019 May;7(5):523-533.doi:10.32622/ijrat.752019326.

Dass R, Jaiswal S, Gupta G. Formulation and evaluation of febuxostat fast disintegrating tablet. Indo Am J Pharm. 2014; 4:2928-2936.

Asif U, Sherwani AK, Akhtar N: Formulation development and optimization of febuxostat tablets by direct compression method. Adv Polym Technol. 2016;35:1-7. doi:10.1002/adv.21536.

Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008 Dec;4(6):1209–1220.doi:10.2147%2Ftcrm.s3310; PMID: 19337428;PMCID: PMC2643102.

Tang J, Bao J, Shi X, Sheng X, Su W. Preparation, Optimization, and in vitro-in vivo evaluation of febuxostat ternary solid dispersion. J Microencapsul. 2018 Aug 18;35(5):454-466.doi: 10.1080/02652048.2018.1526339;PMID: 30229692.

Yin YF, Guo Y, Ding Song, Duan XC, Zheng XC, Zhong T, Zhang S, Yao X, Xu M, Zhang Q, Zhang X. Improving solubility and oral bioavailability of febuxostat by polymer-coated nanomatrix. AAPS PharmSciTech. 2017 Oct 27:1-7. doi: 10.1208/s12249-017-0905-z.

Bhide P, D’cunha J, FernandesN.Development and evaluation of febuxostat sublingual tablet formulation. Int J Pharm Res. 2018 Apr;10(2):1-8.

Sharma M, Parmar K,Baria A, Patel TM, Lalani R, Parikh RK. Gastro retentive tablet of febuxostat: formulation, drug release dynamics, and factorial design. World J Pharm Res. 2015;4(1):1063-1084.

Ahmed A, Abdelhafez WA, Ahmed I, Alaa AK. Formulation and characterization of nanosizedethosomal formulations of antigout model drug (febuxostat) prepared by cold method: in vitro/ ex vivo and in vivo assessment. AAPS PharmSciTech. 2020; 1(31):1-13.doi:10.1208/s12249-019-1556-z.

Vimalson C, Parimalakrishnan S, Jeganathan NS, Anbazhagan S. Solid dispersion technique to enhance the solubility and dissolution of febuxostat a bcs class II drug. Int J App Pharm. 2019;11(1):241-246. doi:10.22159/ijap.2019v11i1.30539.

Reddy SM, Sundari TP. Formulation and evaluation of nanoemulsion for solubility enhancement of febuxostat. IJSDR. 2019 Jan;4(1):118-128.

HabibBA ,El-SamiaeAS, HoussienyBM, TagR.Formulation, characterization, optimization, and in-vivo performance of febuxostat self-nano-emulsifying system loaded sublingual films. Drug Deliv. 2021Jun 26; 28(1):1321-1333. doi:10.1080/10717544.2021.1927247.

Geetha G, Poojitha U, Khan A. Various techniques for preparation of nanosuspension- a review. Int J Pharm Sci Rev Res. 2014 Sept;3(9):30-37.

Jadgav P, Yadav A. Formulation, optimization, and in vitro evaluation of polymeric nanosuspension of flurbiprofen. Asian J Pharm Clin Res. 2019; 12(11): 183-191.

Patel VR, Agrawal YK. Nanosuspensions: promising drug delivery systems.

J. Adv. Pharm. Technol. Res. 2011 Apr;2(2):81-87. doi:10.4103%2F2231-4040.82950;PMCID: PMC3217698; PMID: 22171298.

Eerdenbrugha BV, Froyenb L, HumbeeckbJV, Martensc JA, AugustijnsP, Mooter G. Drying of crystalline drug nanosuspension: The importance of surface hydrophobicity on dissolution behaviour upon redispersion. Eur. J. Pharm. Sci.2008 Jul 3;35:127–135. doi: https://doi.org/10.1016/j.ejps.2008.06.009.

Sutradhar KB, Sabera K, Luna IP. Increasing possibilities of nanosuspension. J Nanotechnol. 2013:1-12. doi: 10.1155/2013/346581.

Kilor V, Sapkal N, Daud A, Humne S, Gupta T. Development of stable nanosuspension loaded oral films of glimepiride with improved bioavailability. Int J Appl Pharm .2017; 9(2): 28-33.

Aher SS, Malsane ST, Saudagar RB. Nanosuspension: an overview. Int J Curr Pharm Res. 2017; 9(3): 9-23.

Degobert G, Aydin D, Lyophilization of nanocapsules: instability sources, formulation and process parameters. Pharmaceutics. 2021 July 21;13:1-26.doi: 10.3390/pharmaceutics13081112.PMID: 34452072, PMCID: PMC8400524.

Ahmed HI, Ibrahim, Rosqvist E, Smatt JH, Ibrahim HM, Ismael HR, Afouna MI, Samy AM, Rosenholm JM. Formulation and optimization of lyophilized nanosuspension tablets to improve the physicochemical properties and provide immediate release of silymarin. Int. J. Pharm. 2019 Apr 1;563:217-227.doi:10.1016/j.ijpharm.2019.03.064; PMID: 30946894.

Telange DR, Denge R, Patil AT, Umekar MJ, Gupta SV, DaveVS.Pentaerythritol as an excipient/solid dispersion carrier for improved solubility and permeability of ursodeoxycholic acid. J Excp Food Chem. 2018 Sept;9(3):80-95.

Rad RT, Mortazavi SA, Vatanara A, Dadashzadeh S. Enhanced dissolution rate of tadalafil nanoparticles prepared by sonoprecipitation technique: optimization and physicochemical investigation.Iran J Pharm Res. 2017;6(4):1335-1348.PMID: 29721025; PMCID: PMC5843297.

Dhore PW, Dave VS, Saoji SD, Gupta D, Raut NA. Influence of carrier (polymer) type and drug-carrier-ratio in the development of amorphous dispersions for solubility and permeability enhancement of ritonavir. J Excipients and Food Chem. 2017; 8(3):1–18.

Hamidi HA, Edwards AA, Mohammad MA, Nokhodchi A. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations. Colloids Surf B Biointerfaces. 2010; 76: 170-178.doi: 10.1016/j.colsurfb.2009.10.030.

Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S. Formulation, optimization and in vitro–in vivo evaluation of febuxostat nanosuspension. Int J Pharm. 2015; 478:540-552.doi:10.1016/j.ijpharm.2014.12.003.

Paswan SK, Saini TR. Comparative evaluation of in vitro drug release methods employed for nanoparticle drug release studies, dissolution technologies. Dissolution Technol. 2021 Nov: 30-38. doi:10.14227/DT280421P30.

Pongpeerapat A, Itoh K, Tozuka Y. Formation and stability of drug nanoparticles obtained from drug/pvp/sds ternary ground mixture. J Drug DelivSciTechnol. 2004;14(6):441–447.

Ding Z, Wang L, Xing Y, Zhao Y, Wang Z, Han J. Enhanced oral bioavailability of celecoxibnanocrystalline solid dispersion based on wet media milling technique: formulation, optimization and in vitro/ in vivo evaluation.Pharmaceutics. 2019 Jul 19;328:1-18. doi: 10.3390/pharmaceutics11070328;PMID: 31336734; PMCID: PMC6680726.

Kuk DH, Ha ES, HaDH, SimWY, LeeSK, Jeong JS, Kim JS , Baek HI, Park H, ChoiDH,Yoo JW , Jeong SH, Hwang SJ, Kim MS. Development of a resveratrol nanosuspension using the antisolvent precipitation method without solvent removal based on a quality by design (QbD) approach. Pharmaceutics.2019 Dec 17: 1-22. doi:10.3390/pharmaceutics11120688.

Zhuang Ding y, Lili Wang y, Yangyang Xing, Yanna Zhao, Zhengping Wang and Jun Han. Enhanced oral bioavailability of celecoxibnanocrystalline solid dispersion based on wet media milling technique: formulation, optimization and in vitro/in vivo evaluation. Pharmaceutics.2019;11:328. doi:10.3390/pharmaceutics11070328.

Patel GV, Patel VB, Pathak A, Rajput SJ. Nanosuspension of efavirenz for improved oral bioavailability: formulation, optimization, in vitro, in situ and in vivo evaluation.DrugDevInd Pharm. 2013 Jan 16:1-12. doi: 10.3109/03639045.2012.746362.

Sundari PT, Lad K. Physico-chemical characterization and in vitro evaluation of febuxostat.Asian J Pharm. 2016 Apr;10(2):62-69.

Anjane M, Agrawal S, Khan A. Formulation and evaluation of nanosuspension of valsartan.Int J Curr Pharm Res. 2018; 10(2): 68-74.

DoppalapudiS,Suryadevara V, Jujala C. Formulation and evaluation of febuxostat fast dissolving tablets using entadascandensseed starch and poloxamer-188 as superdisintegrants. IntJ app pharm.2019 Aug 6;11(5):241-250. doi:10.22159/ijap.2019v11i5.34779.

Deshkar SS, Sonkamble KG, Mahore JG. Formulation and optimization of nanosuspension for improving solubility and dissolution of gemfibrozil. Asian J Pharm Clin Res 2019;12(1):157-163. doi:10.22159/ajpcr.2019.v12i1.26724.

Mohapatra PK, Sireesha, Rathore V, Verma HC, Rath BP, Sahoo S. Fabrication and in vitro characterization of a novel nanosuspension of telmisartan: a poorly soluble drug prepared by antisolvent precipitation technique using 33 factorial design. Int J App Pharm. 2020;12(5):286-294.doi:10.22159/ijap.2020v12i5.38865.

Taani BL, Khanfar A, Alsuod OA. Enhancement of the release of curcumin by the freeze-drying technique using insulin and neusilin as carriers. Int J App Pharm. 2018;10(3):42-48. doi:10.22159/ijap.2018v10i3.24429.

Published

25-08-2022

How to Cite

HADKE, A., PETHE, A., VAIDYA, S., & DEWANI, S. (2022). FORMULATION DEVELOPMENT AND CHARACTERIZATION OF LYOPHILIZED FEBUXOSTAT NANOSUSPENSION. International Journal of Applied Pharmaceutics, 14(6). https://doi.org/10.22159/ijap.2022v14i6.45614

Issue

Section

Original Article(s)